Shares of Dynavax Technologies Corp. (NASDAQ: DVAX) saw a handy gain early on Wednesday after the company announced that it received a recommendation from the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP).
Essentially the ACIP voted unanimously in favor of including Heplisav-B on its list of recommended products for use to vaccinate adults against hepatitis B. Heplisav-B was approved by the U.S. Food and Drug Administration (FDA) in November 2017 for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Ultimately, the receipt of the ACIP recommendation is a key step in providing patients with broad access to Heplisav-B. Medical policies of many insurance plans and institutions require ACIP recommendation before a vaccine is covered or available to their patients.
Dynavax commercially launched Heplisav-B in the United States in January 2018, and it announced Tuesday that the field sales team will begin actively selling Heplisav-B next week.
Eddie Gray, CEO of Dynavax, commented:
With the ACIP’s recommendation, HEPLISAV-B has cleared an important milestone needed to position Dynavax to meet our long-term commercial goals. Additionally, this recognition emphasizes the important role of HEPLISAV-B in the prevention of hepatitis B infection in adults, reinforcing our belief that our unique two-dose vaccine with demonstrated higher rates of protection versus ENGERIX-B, and a safety profile similar to three-dose vaccines, will become the new standard of care for adults.
Shares of Dynavax were last seen up about 2% at $17.65 on Wednesday, with a consensus analyst price target of $29.00 and a 52-week range of $3.90 to $24.45.
The Average American Has No Idea How Much Money You Can Make Today (Sponsor)
The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.
But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.
Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.